A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease

International Journal of Geriatric Psychopharmacology

Volumn 1, Issue 2, 1998, Pages 55-65

  Corey Bloom, J ^a   Anand, R ^a   Veach, J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease treatment; Antidementia medication

Indexed keywords

CHOLINESTERASE INHIBITOR; RIVASTIGMINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT OUTCOME;

EID: 0031902795     PISSN: 13648233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)